CV6 Therapeutics Appoints Dr. Chris Takimoto to Board as CV6-168 Advances Through Phase 1a
BELFAST, COUNTY DOWN, UNITED KINGDOM, June 2, 2026 /EINPresswire.com/ -- CV6 Therapeutics today announced the appointment of internationally recognized oncology drug developer Dr. Chris Takimoto to its Board of Directors as the company advances its lead …